Introduction {#s1}
============

Fabry disease (FD) is an X-linked lysosomal storage disorder with estimated incidence rates of 1:37,000 for the classical Fabry phenotype and 1:3,100 for a late-onset disease variant (Spada et al., [@B76]; Mechtler et al., [@B53]). It can be caused by more than 500 different mutations of the lysosomal α-galactosidase A (α-Gal A) gene (Gal et al., [@B20]; Saito et al., [@B68]). Those mutations lead to deficient activity, reduction or depletion of α-Gal A, followed by impaired degradation of glycosphingolipids and subsequent accumulation of globotriaosylceramide (Gb3) in a variety of tissues, including vascular endothelial cells and neurons (Desnick et al., [@B15]; Bangari et al., [@B4]). In general, males are more affected by the α-Gal A mutations, but also heterozygote females have a significant risk for major organ involvement due to random X-inactivation causing variable expression of α-Gal A and decreased quality of life (Wilcox et al., [@B87]). One of the earliest symptoms of FD is pain due to small-fiber neuropathy, which affects the majority of patients already in early childhood. It can manifest as episodic crises with pain attacks originating in the extremities that can last for several days or even weeks, or chronic pain characterized by burning and tingling paraesthesia (Germain, [@B21]; Ginsberg, [@B22]). The origin of this pain phenotype presumably lies in accumulation of glycolipids within peripheral nerves and/or dorsal root ganglion (DRG) somata that might lead to degeneration of small sensory fibers (Kocen and Thomas, [@B35]; Ohnishi and Dyck, [@B58]; Bangari et al., [@B4]; Godel et al., [@B23]).

Investigating FD specific pathogenesis in Fabry patients is difficult and limited to molecular analyses of tissue biopsies and clinical neurophysiology techniques. It has been found that both motor and sensory conduction velocities are decreased, whereas vibratory, cold, and heat thresholds are elevated in Fabry patients (Sheth and Swick, [@B72]; Dutsch et al., [@B16]; Uceyler et al., [@B83]; Namer et al., [@B54]). In addition, the proportion of mechano-responsive C-fibers is reduced in patients compared to healthy controls (Namer et al., [@B54]). To investigate the molecular and physiological mechanisms underlying the pathology of FD, α-galactosidase A deficient mice \[α-Gal A^(−/0)^\] were generated which share many symptoms with Fabry patients, including altered temperature sensitivity and pain perception (Ohshima et al., [@B59]; Lakoma et al., [@B41]; Uceyler et al., [@B81]; Namer et al., [@B54]).

Although FD constitutes a monogenic disease with loss of function mutations of the α-Gal A gene causing the disease, other genes and/or gene products might be indirectly regulated during disease progression and could play important roles in the manifestation of disease-specific pathologies and symptoms, like the development of small-fiber neuropathy. In the current study we therefore performed mRNA microarray expression profiling of DRG samples from α-Gal A^(−/0)^ mice aged \> 20 weeks when the disease is fully developed to investigate the mRNA signatures associated with FD peripheral nerve neuropathy.

Methods {#s2}
=======

Animals
-------

Male α-galactosidase A^(−/0)^ (α-Gal A^(−/0)^; background C57BL/6; provided by Dr. A. Kulkarni, National Institute of Health, NIDCR, Bethesda, USA) (Ohshima et al., [@B59]) and wildtype C57BL/6J mice aged 20-24 weeks were inbred and housed under specific pathogen-free (SPF) conditions. For microarray expression profiling mice from the separate inbred colonies were used, whereas for RT-qPCR validation, α-Gal A^(−/0)^ mice backcrossed with wildtype C57BL/6J mice and wildtype C57BL/6J mice were used to control for inbred colony effects. Animals were maintained at constant room temperature of 24°C on a 12 h light/dark cycle with lights on from 07:00 to 19:00 and had *ad libitum* access to autoclaved pelleted food and water. All animals were treated in accordance with the Ethics Guidelines of Animal Care (Medical University of Innsbruck), as well as the European Communities Council Directive of 22 September 2010 on the protection of animals used for scientific purposes (2010/63/EU), and approved by the Austrian National Animal Experiment Ethics Committee of the Austrian Bundesministerium für Wissenschaft und Forschung (permit number BMWF-66.011/0054-WF/V/3b/2015).

Tissue collection
-----------------

For microarray expression profiling eight adult mice (aged between 20 and 24 weeks) per group, whereas for RT-qPCR validation six adult mice (aged between 20 and 24 weeks) per group, were deeply anesthetized with isoflurane and euthanized by decapitation. Spinal cords were removed, lumbar DRGs L3-L5 (containing the cell bodies of primary afferents that project into the hind paw) harvested and flash-frozen in liquid nitrogen. Samples were kept at −80°C until further processing. For microarray expression profiling, DRGs from two mice were pooled for the final tissue sample.

Microarray expression profiling
-------------------------------

Genome-wide expression profiling was carried out by IMGM Laboratories (Munich, Germany) using Agilent SurePrint G3 Mouse GE 8 × 60K Microarrays in combination with a one-color based hybridization protocol. Microarray signals were detected using the Agilent DNA Microarray Scanner.

Total RNA including small RNAs was isolated using the miRNeasy Mini Kit (Qiagen) according to the manufacturer\'s instructions and eluted in 40 μl RNase-free water. RNA concentration and purity was determined on a NanoDrop ND-1000 spectral photometer (Peqlab). Samples were analyzed using the RNA 6000 Nano LabChip Kit (Agilent Technologies) on a 2100 Bioanalyzer (Agilent Technologies). For mRNA analysis, total RNA samples were spiked with *in vitro* synthesized polyadenylated transcripts (One-Color RNA Spike-In Mix, Agilent Technologies), reverse transcribed into cDNA and then converted into Cyanine-3 labeled complementary RNA (Low Input Quick-Amp Labeling Kit One-Color, Agilent Technologies) according to the manufacturer\'s instructions. cRNA concentration, RNA absorbance ratio, and Cyanine-3 dye concentration were recorded using a NanoDrop ND-1000 UV-VIS spectral photometer, and quality of labeled cRNA was analyzed using the RNA 6000 Nano LabChip Kit (Agilent Technologies) on a 2100 Bioanalyzer (Agilent Technologies). Following cRNA clean-up and quantification, Cyanine-3-labeled cRNA samples were fragmented and prepared for one-color-based hybridization (Gene Expression Hybridization Kit, Agilent Technologies) and hybridized at 65°C for 17 h on Agilent SurePrint G3 Mouse GE 8 × 60K Microarrays. After hybridization, microarrays were washed with increasing stringency using Triton X-102 supplemented Gene Expression Wash Buffers (Agilent Technologies) followed by drying with acetonitrile (Sigma). Fluorescence signals were detected on an Agilent DNA Microarray Scanner and extracted using feature extraction software (Agilent Technologies). The data discussed in this publication have been deposited in NCBI\'s Gene Expression Omnibus (Edgar et al., [@B17]) and are accessible through GEO Series accession number [GSE104625](GSE104625) (<https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE104625>).

Bioinformatics analyses
-----------------------

GeneSpring GX 13.0 analysis software (Agilent Technologies) was used to normalize and analyze the microarray raw data. Data were normalized using non-parametric quantile normalization. Groups were compared using Welch\'s approximate *t*-test (unpaired unequal variances) and *p*-values corrected for multiple testing using the algorithm of Benjamini and Hochberg (Benjamini and Hochberg, [@B5]), controlling for false discovery rate (FDR). Differential expression between the two groups was determined by calculating fold changes of the averaged normalized expression values. Significantly regulated mRNAs were identified by applying filters on fold changes (absolute fold change ≥ 1.2 or ≥2) and *p*-values (*p* ≤ 0.01). Chip array data were further processed by *R statistics* statistical software package (R Development Core Team, [@B66]) and Volcano plots prepared using R statistics *ggplot function*. Only genes with uncompromised hybridization values in all individual samples were used for the current analysis.

Protein-protein interaction analysis
------------------------------------

Protein-protein interactions (PPIs) were investigated for the significantly regulated mRNAs using the STRING Database v. 10.5 (<http://www.string-db.org>) (Szklarczyk et al., [@B77]), which includes direct and indirect protein associations collected from different databases. Interaction networks were prepared using medium confidence scores (0.40) and clustered using MCL clustering algorithm (inflation parameter: 3). Disconnected nodes were hidden from the network.

Functional enrichment and pathway analysis
------------------------------------------

Functional enrichment and pathway analyses were also performed using the STRING Database v. 10.5 (<http://www.string-db.org>). Classification systems tested were Gene Ontology and KEGG functional annotation spaces, employing Fisher\'s exact test followed by a correction for multiple testing (FDR). Only enriched pathways with FDR corrected *p* \< 0.05 are reported.

RT-qPCR validation of regulated genes
-------------------------------------

Reverse transcription quantitative polymerase chain reaction (RT-qPCR) validation of regulated genes was performed using TaqMan Gene Expression Assays (Thermo Fisher Scientific) in an Applied Biosystems 7500 Fast Real-Time PCR System (Thermo Fisher Scientific).

Total RNA was extracted using peqGOLD TriFast reagent (Peqlab) according to the manufacturer\'s instructions. The quality and quantity of RNA was evaluated using NanoDrop 2000 (Thermo Scientific). Reverse transcription of mRNA was performed as previously described (Langeslag et al., [@B43]). Genes of interest were analyzed by RT-qPCR using the following TaqMan Gene Expression Assays (Thermo Fisher Scientific): Mm00557794_m1 (Amz1), Mm00476032_m1 (Atf3), Mm01299527_m1 (Dnah8), Mm01311685_m1 (Dnase1l3), Mm00469610_m1 (Ecel1), Mm00521881_m1 (Meig1), Mm00505317_m1 (Ncapg2), Mm00443523_m1 (Opn4), Mm01279059_m1 (Rnf39), Mm00509406_m1 (Samd8), Mm00555659_m1 (Dock4), Mm03646971_gH (Gm1987), Mm02391771_g1 (Hdac1), Mm00440480_m1 (Nnat), Mm00452229_m1 (Pmepa1), Mm01188211_m1 (S100pbp), Mm00521530_m1 (Slc51a), Mm00628467_m1 (Syt15), Mm00503605_m1 (Tmem25), Mm00836474_m1 (Zfp932), Mm00446968_m1 (Hprt), Mm01352363_m1 (Sdha), and Mm00441941_m1 (Tfrc). Experimental procedures were performed according to the TaqMan Gene Expression Assays protocol. The reactions were loaded on MicroAmp Fast Optical 96-well reaction plates (Thermo Fisher Scientific) and placed in the Applied Biosystems 7500 Fast Real-Time PCR System (Thermo Fisher Scientific). The PCR cycle protocol used was: 10 min at 95°C, 40 two-step cycles of 15 s at 95°C and 1 min at 60°C. Each sample was run in duplicates alongside non-template controls. Threshold was set manually at 0.1 and threshold cycle (C~T~) was used as a measure of initial RNA input. Relative fold changes in gene expression were calculated using the 2^−ΔΔCT^ method. All fold changes were expressed relative to the respective expression in wildtype mice and analyzed using Welch\'s *t*-test. Three genes (i.e., Hprt, Sdha and Tfrc) were used as reference genes. All three reference genes were found to be stably expressed in both groups of animals, as indicated by geNorm, Normfinder, and Bestkeeper software packages.

Results {#s3}
=======

mRNA expression profile of fabry mouse dorsal root ganglia
----------------------------------------------------------

Using microarray expression profiling we found that in total 812 genes from the overall 21,736 detected mRNAs were significantly different between DRG samples from wildtype and α-Gal A^(−/0)^ mice (criteria *p* ≤ 0.01, absolute fold change ≥ 1.2) (Figure [1](#F1){ref-type="fig"}). Of those, 506 genes were significantly upregulated and 306 genes were significantly downregulated as compared to wildtype controls. More stringent filtering (criteria *p* ≤ 0.01, absolute fold change ≥ 2) of those significantly regulated genes revealed an assessable number of 78 genes in total (Figure [2](#F2){ref-type="fig"}). Using these criteria 41 genes were significantly upregulated, of which 29 showed FDR corrected *p* ≤ 0.1 (Table [1](#T1){ref-type="table"}). Furthermore, 31 genes remained significantly downregulated, of which 27 showed FDR corrected *p* ≤ 0.1 (Table [2](#T2){ref-type="table"}). PPI analysis (STRING Database) neither revealed clusters of interacting proteins nor enriched pathways, due to the small number of input genes. Thus, for in depth PPI analysis all significantly regulated genes (less stringent filtering, criteria *p* ≤ 0.01, absolute fold change ≥ 1.2) were used.

![Volcano plot microarray data. Color green, *p* ≤ 0.01, fold change ≥ 1.2; labels, *p* ≤ 0.01, fold change ≥ 2.0; dot size represents relative expression values of wildtype mice.](fnmol-10-00449-g0001){#F1}

![Heatmap of significantly regulated genes.](fnmol-10-00449-g0002){#F2}

###### 

Raw expression values, fold changes and statistical analysis for significantly *upregulated* genes.

  **NCBI RefSeq ID**             **Gene symbol**   **Gene name**                                                            **Expression α-Gal A^(−/0)^**   **Expression wildtype**   **Fold change**   ***p*-value**   **FDR**
  ------------------------------ ----------------- ------------------------------------------------------------------------ ------------------------------- ------------------------- ----------------- --------------- ---------
  [NM_001277925](NM_001277925)   Ecel1             Endothelin converting enzyme-like 1                                      3,723                           282                       12.3              0.0021          0.1166
  [NM_001099632](NM_001099632)   Rnf39             Ring finger protein 39                                                   1,048                           138                       7.2               \<0.0001        0.0038
  [NM_007870](NM_007870)         Dnase1l3          Deoxyribonuclease 1-like 3                                               286                             39                        7.1               \<0.0001        0.0028
  [BC096660](BC096660)           Tmem181b-ps       Transmembrane protein 181B, pseudogene                                   290                             55                        5.1               0.0054          0.1676
  [NM_173405](NM_173405)         Amz1              Archaelysin family metallopeptidase 1                                    1,865                           476                       3.7               0.0001          0.0327
  [NM_013887](NM_013887)         Opn4              Opsin 4 (melanopsin)                                                     149                             40                        3.7               \<0.0001        0.0117
  [XR_105403](XR_105403)         A930033H14Rik     RIKEN cDNA A930033H14 gene                                               215                             58                        3.6               \<0.0001        0.0089
  [DQ459435](DQ459435)           Gm4924            Predicted gene 4924                                                      2,969                           811                       3.4               0.0003          0.0548
  [NM_013811](NM_013811)         Dnah8             Dynein, axonemal, heavy chain 8                                          552                             162                       3.3               \<0.0001        0.0044
  [NM_053110](NM_053110)         Gpnmb             Glycoprotein (transmembrane) nmb                                         446                             143                       3.0               0.0081          0.1909
  [NM_026528](NM_026528)         2700060E02Rik     RIKEN cDNA 2700060E02 gene                                               242                             79                        3.0               0.0015          0.0992
  [NM_133762](NM_133762)         Ncapg2            Non-SMC condensin II complex, subunit G2                                 641                             216                       2.8               \<0.0001        0.0181
  [NM_007498](NM_007498)         Atf3              Activating transcription factor 3                                        1,776                           611                       2.7               0.0003          0.0524
  [NM_001177470](NM_001177470)   Gm7325            Predicted gene 7325                                                      845                             304                       2.6               0.0001          0.0324
  [NM_008579](NM_008579)         Meig1             Meiosis expressed gene 1                                                 712                             272                       2.5               \<0.0001        0.0168
  [NM_019465](NM_019465)         Crtam             cytotoxic and regulatory T cell molecule                                 102                             41                        2.4               0.0009          0.0784
  [NM_008579](NM_008579)         Meig1             Meiosis expressed gene 1                                                 287                             114                       2.4               \<0.0001        0.0059
  [NM_025876](NM_025876)         Cdk5rap1          CDK5 regulatory subunit associated protein 1                             487                             191                       2.4               0.0010          0.0839
  [NM_023434](NM_023434)         Tox4              TOX high mobility group box family member 4                              480                             191                       2.4               0.0004          0.0609
  [NM_013473](NM_013473)         Anxa8             Annexin A8                                                               142                             60                        2.3               0.0076          0.1879
  [NM_008682](NM_008682)         Nedd1             Neural precursor cell expressed, developmentally down-regulated gene 1   192                             81                        2.3               0.0001          0.0321
  [NM_001037928](NM_001037928)   Gm11992           Predicted gene 11992                                                     172                             74                        2.3               0.0025          0.1233
  [NM_026251](NM_026251)         Patl2             Protein associated with topoisomerase II homolog 2 (yeast)               226                             97                        2.2               0.0002          0.0392
  [NM_031202](NM_031202)         Tyrp1             Tyrosinase-related protein 1                                             2,358                           983                       2.2               0.0008          0.0755
  [NM_011933](NM_011933)         Decr2             2-4-dienoyl-Coenzyme A reductase 2, peroxisomal                          3,844                           1,597                     2.2               0.0020          0.1141
  [NM_010871](NM_010871)         Naip6             NLR family, apoptosis inhibitory protein 6                               145                             65                        2.2               0.0017          0.1073
  [NM_177576](NM_177576)         Sun3              Sad1 and UNC84 domain containing 3                                       109                             50                        2.2               0.0067          0.1815
  [NM_026789](NM_026789)         Wdr65             WD repeat domain 65                                                      1,675                           726                       2.1               0.0001          0.0290
  [NM_001033293](NM_001033293)   Uap1l1            UDP-N-acteylglucosamine pyrophosphorylase 1-like 1                       3,662                           1,579                     2.1               0.0001          0.0291
  [NM_026358](NM_026358)         Mgarp             Mitochondria localized glutamic acid rich protein                        421                             191                       2.1               0.0001          0.0279
  [NM_009659](NM_009659)         Alox12b           Arachidonate 12-lipoxygenase, 12R type                                   135                             63                        2.1               0.0011          0.0869
  [NM_001166630](NM_001166630)   Dynlt1c           Dynein light chain Tctex-type 1C                                         16,719                          7,247                     2.1               0.0081          0.1909
  [NM_007413](NM_007413)         Adora2b           Adenosine A2b receptor                                                   1,478                           667                       2.1               0.0008          0.0771
  [AK031397](AK031397)           Hps1              Hermansky-Pudlak syndrome 1 homolog (human)                              156                             74                        2.0               0.0010          0.0850
  [NM_020574](NM_020574)         Kcne3             Potassium voltage-gated channel, Isk-related subfamily, gene 3           159                             76                        2.0               0.0001          0.0332
  [NM_001145953](NM_001145953)   Lgals3            Lectin, galactose binding, soluble 3                                     19,457                          8,721                     2.0               0.0010          0.0850
  [NM_183187](NM_183187)         Fam107a           Family with sequence similarity 107, member A                            277                             132                       2.0               0.0067          0.1813
  [NM_013710](NM_013710)         Fgd2              FYVE, RhoGEF and PH domain containing 2                                  314                             149                       2.0               0.0053          0.1650
  [NM_026283](NM_026283)         Samd8             Sterile alpha motif domain containing 8                                  362                             171                       2.0               \<0.0001        0.0065
  [NM_001199948](NM_001199948)   Dynlt1f           Dynein light chain Tctex-type 1F                                         12,240                          5,496                     2.0               0.0029          0.1333
  [XR_002334](XR_002334)         Lrrc31            Leucine rich repeat containing 31                                        689                             325                       2.0               0.0008          0.0755

###### 

Raw expression values, fold changes, and statistical analysis for significantly *downregulated* genes.

  **NCBI RefSeq ID**   **Gene symbol**   **Gene name**                                            **Expression α-Gal A^(−/0)^**   **Expression wildtype**   **Fold change**   ***p*-value**   **FDR**
  -------------------- ----------------- -------------------------------------------------------- ------------------------------- ------------------------- ----------------- --------------- ---------
  NR_033506            Gm3893            Predicted gene 3893                                      74                              1,582                     −22.4             \<0.0001        0.0005
  NR_033123            4933409K07Rik     RIKEN cDNA 4933409K07 gene                               134                             1,332                     −10.5             \<0.0001        0.0002
  NM_001085530         Gm13298           Predicted gene 13298                                     214                             2,104                     −10.4             \<0.0001        0.0028
  NM_001085530         Gm13298           Predicted gene 13298                                     217                             1,989                     −9.8              \<0.0001        0.0002
  NR_033506            Gm3893            Predicted gene 3893                                      92                              628                       −7.1              \<0.0001        0.0044
  AK046830             Prune2            Prune homolog 2 (Drosophila)                             256                             1,279                     −5.3              0.0012          0.0905
  NM_001085530         Gm13298           Predicted gene 13298                                     143                             683                       −5.0              \<0.0001        0.0038
  NM_008228            Hdac1             Histone deacetylase 1                                    577                             2,465                     −4.6              \<0.0001        0.0065
  AK009987             2310058N22Rik     RIKEN cDNA 2310058N22 gene                               342                             1,408                     −4.4              \<0.0001        0.0117
  AK147155             Slc51a            Solute carrier family 51, alpha subunit                  526                             2,093                     −4.3              0.0002          0.0400
  NM_134041            4930427A07Rik     RIKEN cDNA 4930427A07 gene                               74                              303                       −4.2              \<0.0001        0.0102
  NM_145932            Slc51a            Solute carrier family 51, alpha subunit                  130                             513                       −4.1              0.0001          0.0376
  NM_181529            Syt15             Synaptotagmin XV                                         56                              201                       −3.7              0.0001          0.0254
  NM_001193667         Gm1987            Predicted gene 1987                                      981                             3,294                     −3.6              0.0002          0.0400
  NM_027865            Tmem25            Transmembrane protein 25                                 5,609                           18,317                    −3.6              \<0.0001        0.0120
  NM_010923            Nnat              Neuronatin                                               185                             620                       −3.5              \<0.0001        0.0005
  NM_010923            Nnat              Neuronatin                                               233                             773                       −3.5              \<0.0001        0.0001
  NR_015521            1700030C10Rik     RIKEN cDNA 1700030C10 gene                               150                             466                       −3.2              0.0015          0.1002
  NM_172803            Dock4             Dedicator of cytokinesis 4                               1,369                           3,479                     −2.8              0.0003          0.0541
  XM_003945535         LOC101056136      Disks large homolog 5-like                               51                              135                       −2.7              0.0001          0.0326
  NM_008228            Hdac1             Histone deacetylase 1                                    159                             407                       −2.7              0.0004          0.0591
  NM_145563            Zfp932            Zinc finger protein 932                                  1,101                           2,666                     −2.6              \<0.0001        0.0076
  NM_001135567         1190007I07Rik     RIKEN cDNA 1190007I07 gene                               571                             1,387                     −2.6              0.0008          0.0763
  NM_022995            Pmepa1            Prostate transmembrane protein, androgen induced 1       2,274                           5,394                     −2.6              0.0001          0.0378
  AK139097             S100pbp           S100P binding protein                                    100                             239                       −2.5              \<0.0001        0.0117
  NM_175475            Cyp26b1           Cytochrome P450, family 26, subfamily b, polypeptide 1   583                             1,264                     −2.3              0.0008          0.0756
  NM_178420            Nlrx1             NLR family member X1                                     383                             793                       −2.2              0.0015          0.0991
  NM_018857            Msln              Mesothelin                                               81                              172                       −2.2              0.0054          0.1674
  NM_011909            Usp18             Ubiquitin specific peptidase 18                          226                             451                       −2.1              0.0045          0.1552
  NM_029011            Pyroxd2           Pyridine nucleotide-disulphide oxidoreductase domain 2   57                              115                       −2.1              0.0066          0.1804
  NM_198026            Iqcc              IQ motif containing C                                    556                             1,068                     −2.0              \<0.0001        0.0130

Enriched pathways and protein-protein interactions for upregulated mRNAs
------------------------------------------------------------------------

Enrichment analysis of the 506 significantly upregulated genes revealed that a number of KEGG pathways and Gene Ontology processes were enriched, including the KEGG pathway "Lysosome" (KEGG:04142) and the biological process "Ceramide metabolic process" (GO:0006672), both known to constitute major hallmarks of FD pathogenesis (Table [3](#T3){ref-type="table"}).

###### 

Enrichment-analysis for *upregulated* mRNAs in α-Gal A^(−/0)^ vs. wildtype mice using gene ontology and KEGG pathway annotations.

  **Pathway ID**                  **Pathway description**                        **Count in network**   **False discovery rate**
  ------------------------------- ---------------------------------------------- ---------------------- --------------------------
  **KEGG PATHWAYS**                                                                                     
  04142                           Lysosome                                       12                     0.0011
  05204                           Chemical carcinogenesis                        9                      0.0073
  00980                           Metabolism of xenobiotics by cytochrome P450   7                      0.0184
  00480                           Glutathione metabolism                         6                      0.0317
  00511                           Other glycan degradation                       4                      0.0231
  **BIOLOGICAL PROCESSES (GO)**                                                                         
  GO:0008150                      Biological_process                             254                    0.0328
  GO:0009987                      Cellular process                               242                    0.0139
  GO:0044763                      Single-organism cellular process               204                    0.0139
  GO:0008152                      Metabolic process                              184                    0.0328
  GO:1901564                      Organonitrogen compound metabolic process      46                     0.0139
  GO:0033993                      Response to lipid                              30                     0.0462
  GO:0006672                      Ceramide metabolic process                     8                      0.0328
  **CELLULAR COMPONENT (GO)**                                                                           
  GO:0005575                      Cellular_component                             299                    0.0004
  GO:0005623                      Cell                                           273                    0.0004
  GO:0044464                      Cell part                                      273                    0.0004
  GO:0005622                      Intracellular                                  256                    0.0001
  GO:0043226                      Organelle                                      251                    \<0.0001
  GO:0044424                      Intracellular part                             251                    0.0001
  GO:0043227                      Membrane-bounded organelle                     239                    \<0.0001
  GO:0005737                      Cytoplasm                                      228                    \<0.0001
  GO:0043229                      Intracellular organelle                        222                    0.0010
  GO:0043231                      Intracellular membrane-bounded organelle       208                    0.0009
  GO:0016020                      Membrane                                       172                    0.0053
  GO:0044444                      Cytoplasmic part                               164                    \<0.0001
  GO:0044422                      Organelle part                                 151                    0.0309
  GO:0044425                      Membrane part                                  134                    0.0088
  GO:0031224                      Intrinsic component of membrane                116                    0.0149
  GO:0016021                      Integral component of membrane                 112                    0.0211
  GO:0005576                      Extracellular region                           98                     0.0222
  GO:0031982                      Vesicle                                        97                     0.0001
  GO:0005886                      Plasma membrane                                96                     0.0095
  GO:0071944                      Cell periphery                                 96                     0.0186
  GO:0031988                      Membrane-bounded vesicle                       94                     0.0001
  GO:0044421                      Extracellular region part                      91                     0.0044
  GO:0070062                      Extracellular exosome                          77                     0.0004
  GO:0031090                      Organelle membrane                             69                     0.0260
  GO:0044459                      Plasma membrane part                           57                     0.0041
  GO:0005829                      Cytosol                                        49                     0.0335
  GO:0098805                      Whole membrane                                 49                     0.0378
  GO:0005739                      Mitochondrion                                  48                     0.0222
  GO:0031226                      Intrinsic component of plasma membrane         33                     0.0170
  GO:0005887                      Integral component of plasma membrane          30                     0.0434
  GO:0005773                      Vacuole                                        25                     0.0006
  GO:0048471                      Perinuclear region of cytoplasm                25                     0.0041
  GO:0005764                      Lysosome                                       23                     0.0004
  GO:0042470                      Melanosome                                     8                      0.0309
  GO:0030904                      Retromer complex                               4                      0.0200
  GO:0097422                      Tubular endosome                               3                      0.0044
  GO:1990622                      CHOP-ATF3 complex                              2                      0.0186

*Whole genome was used as statistical background*.

Protein-protein interaction (PPI) analysis of significantly upregulated mRNAs revealed a significant PPI enrichment (*p* \< 0.0001; Figure [3](#F3){ref-type="fig"}). The number of actually observed edges (*n* = 328) exceeded the expected number of edges (*n* = 231) by 42%. Furthermore, three clusters of at least five interconnected proteins became apparent. Enrichment analysis of those clusters showed that those genes were involved in different pathways (Table [4](#T4){ref-type="table"}), the red cluster was related to "G-protein coupled receptor signaling" (e.g., GO:0007186), the pink cluster was involved in "retrograde transport" (GO:0042147) and the orange cluster was related to "glutathione transferase activity" (GO:0004364).

![STRING database protein-protein interaction (PPI) network of significantly *upregulated* genes. Cut-off values, *p* ≤ 0.01, fold change ≥ 1.2.](fnmol-10-00449-g0003){#F3}

###### 

GO biological processes and molecular functions of PPI-clusters from *upregulated* mRNAs in α-Gal A^(−/0)^ vs. wildtype mice.

  **Pathway ID**       **Pathway description**                        **Count in network**   **False discovery rate**
  -------------------- ---------------------------------------------- ---------------------- --------------------------
  **RED CLUSTER**                                                                            
  GO:0007186           G-protein coupled receptor signaling pathway   9                      \<0.0001
  GO:0044057           Regulation of system process                   7                      \<0.0001
  GO:0004930           G-protein coupled receptor activity            6                      0.0004
  GO:0008217           Regulation of blood pressure                   5                      \<0.0001
  GO:0007218           Neuropeptide signaling pathway                 4                      0.0004
  **PINK CLUSTER**                                                                           
  GO:0042147           Retrograde transport, endosome to Golgi        5                      \<0.0001
  **ORANGE CLUSTER**                                                                         
  GO:0004364           Glutathione transferase activity               5                      \<0.0001

Enriched pathways and protein-protein interactions for downregulated mRNAs
--------------------------------------------------------------------------

Enrichment analysis for the 306 significantly downregulated genes revealed a variety of regulated pathways, including immune related pathways (e.g., Complement and coagulation cascades, Antigen processing and presentation, Immune system process, Immune responses, etc.), autoimmune diseases (e.g., Systemic lupus erythematosus, Diabetes mellitus Type 1, Autoimmune thyroid disease, Asthma, etc.) and different infection pathways (e.g., Herpes simplex, Staphylococcus aureus, Leishmaniasis, etc.). In addition, "Neuroactive ligand-receptor interaction" (KEGG:04080) and "Vesicle" (GO:0031982) were enriched in the downregulated mRNAs (Table [5](#T5){ref-type="table"}).

###### 

Enrichment-analysis for *downregulated* mRNAs in α-Gal A^(−/0)^ vs. wildtype mice using gene ontology and KEGG pathway annotations.

  **Pathway ID**                  **Pathway description**                                                             **Count in network**   **False discovery rate**
  ------------------------------- ----------------------------------------------------------------------------------- ---------------------- --------------------------
  **KEGG PATHWAYS**                                                                                                                          
  05168                           Herpes simplex infection                                                            12                     0.0003
  04080                           Neuroactive ligand-receptor interaction                                             10                     0.0220
  05164                           Influenza A                                                                         9                      0.0050
  05322                           Systemic lupus erythematosus                                                        8                      0.0007
  05150                           Staphylococcus aureus infection                                                     7                      0.0003
  04514                           Cell adhesion molecules (CAMs)                                                      7                      0.0247
  04145                           Phagosome                                                                           7                      0.0319
  05332                           Graft-versus-host disease                                                           6                      0.0010
  05330                           Allograft rejection                                                                 5                      0.0058
  04940                           Type I diabetes mellitus                                                            5                      0.0100
  05320                           Autoimmune thyroid disease                                                          5                      0.0159
  05140                           Leishmaniasis                                                                       5                      0.0193
  04612                           Antigen processing and presentation                                                 5                      0.0220
  05133                           Pertussis                                                                           5                      0.0220
  05416                           Viral myocarditis                                                                   5                      0.0220
  04610                           Complement and coagulation cascades                                                 5                      0.0247
  05310                           Asthma                                                                              4                      0.0050
  04672                           Intestinal immune network for IgA production                                        4                      0.0220
  **BIOLOGICAL PROCESSES (GO)**                                                                                                              
  GO:0050896                      Response to stimulus                                                                93                     \<0.0001
  GO:0044707                      Single-multicellular organism process                                               75                     0.0471
  GO:0048523                      Negative regulation of cellular process                                             61                     0.0268
  GO:0006950                      Response to stress                                                                  54                     0.0005
  GO:0051239                      Regulation of multicellular organismal process                                      43                     0.0301
  GO:0010033                      Response to organic substance                                                       38                     0.0351
  GO:0002376                      Immune system process                                                               36                     \<0.0001
  GO:0006952                      Defense response                                                                    31                     0.0000
  GO:0051240                      Positive regulation of multicellular organismal process                             30                     0.0222
  GO:0006955                      Immune response                                                                     24                     0.0007
  GO:0007155                      Cell adhesion                                                                       22                     0.0465
  GO:0045087                      Innate immune response                                                              19                     0.0001
  GO:0009607                      Response to biotic stimulus                                                         19                     0.0280
  GO:0051707                      Response to other organism                                                          18                     \<0.0001
  GO:0098609                      Cell-cell adhesion                                                                  17                     0.0178
  GO:0002252                      Immune effector process                                                             14                     0.0080
  GO:0016337                      Single organismal cell-cell adhesion                                                14                     0.0465
  GO:0051962                      Positive regulation of nervous system development                                   14                     0.0465
  GO:0034109                      Homotypic cell-cell adhesion                                                        12                     0.0259
  GO:0009615                      Response to virus                                                                   10                     0.0146
  GO:0022409                      Positive regulation of cell-cell adhesion                                           9                      0.0396
  GO:0019882                      Antigen processing and presentation                                                 7                      0.0077
  GO:0016064                      Immunoglobulin mediated immune response                                             7                      0.0080
  GO:0006959                      Humoral immune response                                                             7                      0.0280
  GO:0002455                      Humoral immune response mediated by circulating immunoglobulin                      6                      0.0015
  GO:0048002                      Antigen processing and presentation of peptide antigen                              5                      0.0280
  GO:0019886                      Antigen processing and presentation of exogenous peptide antigen via MHC class II   4                      0.0080
  GO:0070268                      Cornification                                                                       2                      0.0471
  **CELLULAR COMPONENT (GO)**                                                                                                                
  GO:0005575                      Cellular_component                                                                  183                    0.0002
  GO:0044464                      Cell part                                                                           160                    0.0052
  GO:0005623                      Cell                                                                                160                    0.0057
  GO:0016020                      Membrane                                                                            112                    0.0004
  GO:0044425                      Membrane part                                                                       91                     0.0003
  GO:0031224                      Intrinsic component of membrane                                                     82                     0.0002
  GO:0016021                      Integral component of membrane                                                      80                     0.0002
  GO:0005886                      Plasma membrane                                                                     68                     0.0003
  GO:0071944                      Cell periphery                                                                      68                     0.0005
  GO:0005576                      Extracellular region                                                                62                     0.0252
  GO:0044421                      Extracellular region part                                                           58                     0.0054
  GO:0031982                      Vesicle                                                                             57                     0.0041
  GO:0031988                      Membrane-bounded vesicle                                                            52                     0.0252
  GO:0070062                      Extracellular exosome                                                               49                     0.0016
  GO:0044459                      Plasma membrane part                                                                40                     0.0011
  GO:0005615                      Extracellular space                                                                 25                     0.0252
  GO:0005887                      Integral component of plasma membrane                                               24                     0.0026
  GO:0098797                      Plasma membrane protein complex                                                     16                     0.0011
  GO:0045121                      Membrane raft                                                                       10                     0.0252
  GO:0072562                      Blood microparticle                                                                 6                      0.0252
  GO:0042611                      MHC protein complex                                                                 5                      0.0002
  GO:0042613                      MHC class II protein complex                                                        4                      0.0001
  GO:0035098                      ESC/E(Z) complex                                                                    3                      0.0252

*Whole genome was used as statistical background*.

Also, the PPI analysis of significantly downregulated mRNAs revealed a significant PPI enrichment (*p* \< 0.0001; Figure [4](#F4){ref-type="fig"}). Actually observed edges (*n* = 250) exceeded the expected number of edges (*n* = 134) by 87%. Also for the downregulated mRNAs clusters of interconnected proteins emerged. Enrichment analysis showed three clusters (i.e., green, purple, and cyan) related to the immune system (e.g., Immune system process---GO: 0002376, Immune response---GO:0006955). The blue cluster was associated with gene regulation (e.g., Chromatin modification---GO:0016568) and the rose cluster was related to "G-protein coupled receptor activity" (GO:0004930) (Table [6](#T6){ref-type="table"}).

![STRING database protein--protein interaction (PPI) network of significantly *downregulated* genes. Cut-off values, *p* ≤ 0.01, fold change ≥ 1.2.](fnmol-10-00449-g0004){#F4}

###### 

GO biological processes and molecular functions of PPI-clusters from *downregulated* mRNAs in α-Gal A^(−/0)^ vs. wildtype mice.

  **Pathway ID**       **Pathway description**                                                             **Count in network**   **False discovery rate**
  -------------------- ----------------------------------------------------------------------------------- ---------------------- --------------------------
  **GREEN CLUSTER**                                                                                                               
  GO:0002376           Immune system process                                                               10                     \<0.0001
  GO:0051707           Response to other organism                                                          8                      \<0.0001
  GO:0009615           Response to virus                                                                   7                      \<0.0001
  GO:0002252           Immune effector process                                                             7                      \<0.0001
  GO:0051607           Defense response to virus                                                           6                      \<0.0001
  GO:0045087           Innate immune response                                                              6                      0.0005
  **BLUE CLUSTER**                                                                                                                
  GO:0016568           Chromatin modification                                                              5                      0.0007
  GO:0045814           Negative regulation of gene expression, epigenetic                                  4                      \<0.0001
  **PURPLE CLUSTER**                                                                                                              
  GO:0006952           Defense response                                                                    5                      0.0003
  GO:0002455           Humoral immune response mediated by circulating immunoglobulin                      4                      \<0.0001
  GO:0006958           Complement activation, classical pathway                                            4                      \<0.0001
  GO:0045087           Innate immune response                                                              4                      0.0007
  **ROSE CLUSTER**                                                                                                                
  GO:0004930           G-protein coupled receptor activity                                                 4                      0.0049
  **CYAN CLUSTER**                                                                                                                
  GO:0006955           Immune response                                                                     6                      \<0.0001
  GO:0048002           Antigen processing and presentation of peptide antigen                              5                      \<0.0001
  GO:0019886           Antigen processing and presentation of exogenous peptide antigen via MHC class II   4                      \<0.0001
  GO:0003823           Antigen binding                                                                     4                      \<0.0001
  GO:0034341           Response to interferon-gamma                                                        3                      0.0004
  GO:0042605           Peptide antigen binding                                                             3                      \<0.0001

Ion channel regulation
----------------------

As the sensory deficits of Fabry patients are generally accepted to be caused by changes in the excitability of sensory neurons, we specifically searched our dataset for genes related to ion channels, ion channel function and trafficking. Besides downregulation of voltage-gated sodium and calcium channels (i.e., Scn7a and Cacna1h), we found that several potassium channels and potassium channel associated proteins were differentially expressed (Table [7](#T7){ref-type="table"}). Voltage-gated (i.e., Kcnb2) and calcium activated potassium channel subunits (i.e., Kcnmb1 and Kcnt1), as well as potassium channel tetramerization and interacting proteins (i.e., Kcnip2, Pctd16, and Kctd11) were downregulated in DRGs from FD mice. In contrast, the potassium channel ancillary beta subunit Kcne3 was upregulated. Last but not least, the mechanosensitive ion channel Piezo2 was significantly downregulated. Against all expectation, we found none of the pain-associated transient receptor potential (TRP) channels regulated.

###### 

Raw expression values, fold changes, and statistical analysis for significantly regulated ion channels.

  **NCBI RefSeq ID**             **Gene symbol**   **Gene name**                                                                       **Expression α-Gal A^(−/0)^**   **Expression wildtype**   **Fold change**   ***p*-value**   **FDR**
  ------------------------------ ----------------- ----------------------------------------------------------------------------------- ------------------------------- ------------------------- ----------------- --------------- ---------
  **UPREGULATED GENES**                                                                                                                                                                                                            
  [NM_020574](NM_020574)         Kcne3             Potassium voltage-gated channel, Isk-related subfamily, gene 3                      160                             77                        2.0               0.0001          0.0332
  [NM_001190870](NM_001190870)   Kcne3             Potassium voltage-gated channel, Isk-related subfamily, gene 3                      142                             77                        1.8               0.0001          0.0236
  [NM_001042489](NM_001042489)   Hvcn1             Hydrogen voltage-gated channel 1                                                    215                             133                       1.6               0.0045          0.1545
  [NM_146037](NM_146037)         Kcnk13            Potassium channel, subfamily K, member 13                                           1,721                           1,049                     1.5               0.0000          0.0122
  [NM_001042489](NM_001042489)   Hvcn1             Hydrogen voltage-gated channel 1                                                    312                             217                       1.4               0.0046          0.1565
  **DOWNREGULATED GENES**                                                                                                                                                                                                          
  [NM_031169](NM_031169)         Kcnmb1            Potassium large conductance calcium-activated channel, subfamily M, beta member 1   1,759                           2,621                     −1.6              0.0000          0.0059
  [NM_011028](NM_011028)         P2rx6             Purinergic receptor P2X, ligand-gated ion channel, 6                                523                             682                       −1.4              0.0045          0.1546
  [NM_175462](NM_175462)         Kcnt1             Potassium channel, subfamily T, member 1                                            11,165                          13,232                    −1.3              0.0056          0.1701
  [NM_145703](NM_145703)         Kcnip2            Kv channel-interacting protein 2                                                    1,321                           1,598                     −1.3              0.0027          0.1273
  [NM_026135](NM_026135)         Kctd16            Potassium channel tetramerisation domain containing 16                              947                             1,140                     −1.3              0.0029          0.1327
  [NM_001039485](NM_001039485)   Piezo2            Piezo-type mechanosensitive ion channel component 2                                 1,089                           1,258                     −1.3              0.0085          0.1956
  [NM_021415](NM_021415)         Cacna1h           Calcium channel, voltage-dependent, T type, alpha 1H subunit                        3,547                           4,085                     −1.3              0.0029          0.1327
  [NM_009135](NM_009135)         Scn7a             Sodium channel, voltage-gated, type VII, alpha                                      1,193                           1,366                     −1.2              0.0071          0.1837
  [NM_001098528](NM_001098528)   Kcnb2             Potassium voltage gated channel, Shab-related subfamily, member 2                   1,600                           1,799                     −1.2              0.0061          0.1744
  [NM_153143](NM_153143)         Kctd11            Potassium channel tetramerisation domain containing 11                              1,445                           1,624                     −1.2              0.0051          0.1637

RT-qPCR validation of regulated genes
-------------------------------------

To validate the differentially expressed genes from the microarray expression profiling, we performed RT-qPCR analysis of the top 10 up- and downregulated genes in a separate set of samples from α-Gal A^(−/0)^ mice backcrossed with C57BL/6J mice and C57BL/6J wildtype mice. We found that 9/10 of the upregulated genes (i.e., Rnf39, Opn4, Ecel1, Dnah8, Amz1, Dnase1l3, Meig1, Atf3, and Ncapg2) showed significant upregulation, whereas only one gene (i.e., Samd8) was not regulated (Figure [5A](#F5){ref-type="fig"}). For the downregulated genes, 6/10 genes (i.e., Slc51a, Zfp932, Gm1987, Syt15, Nnat, and Hdac1) were significantly downregulated, and four genes (i.e., Tmem25, S100pbp, Pmepa1, and Dock4) did not show regulation (Figure [5B](#F5){ref-type="fig"}). Thus, differential expression of 75% of the genes selected for RT-qPCR validation could be verified.

![RT-qPCR validation of up- **(A)** and *downregulated* genes **(B)**. ^\*^*p* \< 0.05, ^\*\*^*p* \< 0.01, \#*p* \< 0.1.](fnmol-10-00449-g0005){#F5}

Discussion {#s4}
==========

Neuropathic pain and small-nerve fiber neuropathy are among the first symptoms of Fabry disease and affect the majority of patients already in early childhood. Therefore, the involvement of sensory neurons, whose cell somata are located in DRGs, is evident. However, our study is the first to present a differential gene expression profile of DRGs from α-Gal A^(−/0)^ mice, a recognized mouse model for FD (Ohshima et al., [@B59]; Lakoma et al., [@B41]; Uceyler et al., [@B81]), and wildtype controls. We performed microarray expression profiling and found that 812 genes were significantly deregulated, 506 of them being upregulated and 306 being downregulated. Enrichment analysis revealed that the two pathways "lysosome" and "ceramide metabolic process" were significantly enriched. As FD is part of the broad family of lysosomal storage disorders that all show defects in ceramide metabolism (Platt et al., [@B64]), our results demonstrate the involvement of these two pathways also in DRG neurons and therefore enhance the reliability of the current analysis.

When taking a closer look at the significantly downregulated genes the "immune system" emerged as another disease specific entity. Lysosomal storage disorders in general are associated with deficits in processing of protein antigens and antibody production (Daly et al., [@B13]), and Hawkins-Salsbury et al. ([@B27]) specifically report an immune deficit in Fabry patients. In the present study, enrichment analysis of downregulated genes revealed mainly immune system related pathways and processes, for example different autoimmune diseases, infection pathways and processes like "immune responses" or "antigen processing and presentation" (Table [5](#T5){ref-type="table"}). In this regard, it might be noted that the downregulated purple cluster which includes serine-protease inhibitors (Serpins) might also be involved in nervous system related symptoms. Serpins are known to play a role in coagulation, and loss of serpins might induce a variety of bleeding disorders (Kaiserman et al., [@B31]). It has recently been shown that angiokeratoma, one of the first dermatologic disease presentations in Fabry patients, if present in gastrointestinal mucosa can lead to life-threatening bleeding episodes during coagulation therapy (Oh et al., [@B57]; Kang et al., [@B33]). Interestingly, 30% of Fabry patients show cerebral microbleeds (Kono et al., [@B39]), which together with the downregulated Thrombospondin 1 (Thsd7a) and Thromboxane a2 receptor (Tbxa2r) can be related to a general deficit in blood coagulation pathways. Further analysis of the regulation and impairment of those genes might open up new treatment strategies for cerebral vasculopathy, including cerebral hemorrhage, stroke, or other cerebral lesions associated with FD (Schiffmann and Moore, [@B71]). In a mouse model of neuropathic pain, it has been shown that mice that underwent surgery for chronic constriction injury showed activation of the immune system in higher brain structures (Koks et al., [@B36]). Based on these results it would be interesting to see if this immune activation is also present in brains of FD mice and/or patients.

Enrichment analysis of the upregulated clusters revealed significant enrichment of the "G-protein coupled receptor signaling" and "retrograde transport" pathways. Upregulation of genes in these clusters could be related to hypersensitivity and changes in excitability of DRG nerve fibers as a possible underlying cause of the frequent pain attacks experienced by Fabry patients (Schiffmann and Moore, [@B71]; Uceyler et al., [@B82]). Although the genes in the reported clusters are not directly related to changes in excitability, a number of ion channels were significantly deregulated and could be responsible for the hyperexcitability. Besides downregulation of voltage-gated sodium and calcium channels, different potassium channels and associated proteins showed regulation. In contrast, only Kcne3---a potassium channel ancillary beta subunit known to increase excitability (Abbott et al., [@B1])---was upregulated. To date, knowledge on changes in ion channel expression and function in FD are sparse and controversial. Lakoma et al. ([@B41]) reported increased immunoreactivity for a voltage-gated sodium channel Na~v~1.8 (Scn10a) in skin samples of FD mouse sensory neurons including the free nerve endings. Recently, decreased conductance of sodium currents in dissociated DRG neurons from FD mice was demonstrated (Namer et al., [@B54]). This latter publication also reported activation of voltage-gated potassium channels at more depolarized potentials, supporting a general reduction in FD neuron excitability (Namer et al., [@B54]). With regard to calcium channels it has been shown that Lyso-Gb3 enhances voltage-gated calcium currents in DRGs of FD mice (Choi L. et al., [@B10]), whereas Namer et al. ([@B54]) report decreased voltage-gated calcium currents in α-Gal A^(−/0)^ nociceptors. We also found a downregulation of the mechanosensitive ion channel Piezo2 mRNA, which may possibly be correlated to the decreased number of mechanosensitive fibers found in both human patients and FD mice (Namer et al., [@B54]). With regards to temperature sensitive ion channels it has been shown that expression of Trpv1 was increased, whereas expression of Trpm8 was decreased in skin biopsies of FD mice (Lakoma et al., [@B41], [@B42]), which may be related to the changed thermal thresholds reported in both Fabry patients and mice (Sheth and Swick, [@B72]; Dutsch et al., [@B16]; Uceyler et al., [@B83]; Namer et al., [@B54]). The present unbiased screen for differentially expressed ion channels did not confirm deregulation of Trpv1 or Trpm8 though.

Previous gene expression studies were not performed in neuronal tissues but could still be affected by the same regulating pathways. In α-Gal A^(−/0)^ fibroblasts and endothelial cells K~Ca~3.1 (Kcnn4) was downregulated (Choi et al., [@B11]; Choi J. Y. et al., [@B9]) and the conductance of calcium-activated potassium channels was reduced (Olivan-Viguera et al., [@B60]). Additional gene expression studies have been performed in hepatic, renal and human blood cells (Park et al., [@B63]; Cigna et al., [@B12]; Shin et al., [@B74]). Thrombospondin 2 and 4 have been found to be upregulated in FD kidney cells (Park et al., [@B63]), whereas our results show a downregulation of both Thrombospondin 1 (Thsd7a) and Thromboxane a2 receptor (Tbxa2r) in FD DRGs. Both observations point towards impaired blood coagulation pathways in FD. In the same screen Neuropeptide Y (NPY) was found to be upregulated (Park et al., [@B63]). In the current dataset, a different neuropeptide, Neuropeptide B, was significantly upregulated, which has been shown to be functionally connected with NPY at least in fish (Yang et al., [@B89]). Furthermore, different types of S100 calcium binding proteins, i.e., S100a4/a8/a9 are upregulated in liver and kidney (Park et al., [@B63]), whereas S100pbp (a S100P binding protein) was decreased in FD DRGs in the present screen.

The deregulated genes that emerged from our analysis largely overlap with genes from previous reports on other painful disorders, although the direction of regulation does not always match. Upregulation of the transcription factor Atf3 is in line with previous reports that showed induction of Atf3 in DRGs in different models of nerve injury (Tsujino et al., [@B80]; Shortland et al., [@B75]; Matsuura et al., [@B52]), as well as upon exposure to noxious stimuli (Braz and Basbaum, [@B6]). Also, the adenosine receptor Adora2b which was upregulated in FD mice promotes chronic pain through neuro-immune interactions (Hu et al., [@B28]). The Tyrp1 gene has been associated with thermal nociception, and loss of function mutations generate deficits in thermal nociception (Fortin et al., [@B18]). Furthermore, Cdk5-mediated phosphorylation modulates Trpv1 function (Jendryke et al., [@B29]). Upregulation of these two latter genes in FD may therefore be associated with burning and tingling paraesthesias reported in Fabry patients (Germain, [@B21]; Ginsberg, [@B22]). Neuronatin (Nnat), which is significantly downregulated in the current screen, was upregulated in DRGs after sciatic nerve injury and associated with mechanical hypersensitivity (Chen et al., [@B8]). Several genes in the clusters that emerged from the current analysis, are associated with G-protein signaling and are controversially discussed (Pan et al., [@B62]). The somatostatin receptor Sstr2 in the red cluster is downregulated after sciatic nerve ligation (Shi et al., [@B73]), but elevated in response to intestinal inflammation (Van Op den Bosch et al., [@B84]). The endothelin receptor Ednrb attenuates cancer-induced pain (Viet et al., [@B86]), and the angiotensin receptor Agtr1b has been proposed as a biomarker for pain (Grace et al., [@B24]). All clusters involve genes that have been associated with exacerbated pain phenotypes in clinical or preclinical studies. Single nucleotide polymorphisms in the serotonin receptor gene Htr2a in the rose gene cluster are associated with pain-phenotypes as a genetic predisposition to musculoskeletal pain (Nicholl et al., [@B56]). The hypocretin receptor Hcrtr1 is associated with migraine (Rainero et al., [@B67]), and Kalirin (Klrn), a Rho guanine nucleotide exchange factor, is required for persistent nociceptive activity dependent synaptic long-term potentiation (Lu et al., [@B48]). The pink cluster contains genes that are mainly associated with retrograde transport. Vps26a is increased following spinal nerve ligation in the spinal dorsal horn and is required for recycling of mGluR5 and plasticity at excitatory synapses (Lin et al., [@B47]). Vps35, another regulated gene product from our screen, forms a complex with Vps26a (Kim et al., [@B34]) and is also highly associated with members from the sorting nexin family (e.g., Snx6 and Snx8 from our screen). Individuals with polymorphisms in Gluthatione-S-transferase genes found in the orange gene cluster are more likely to develop neuropathy during oxaliplatin treatment (Kanat et al., [@B32]). In addition, activation of Aldh2, a gene associated with the glutathione pathway, reduces nociception in acute inflammatory pain (Zambelli et al., [@B90]). This gene is regulated by Aldh3a1 which was deregulated in the current analysis (Chen et al., [@B7]). The green cluster contained the gene Tnfsf10, a member of the Tumor necrosis factor superfamily. Tnfsf10 is increased by excitotoxic spinal cord injury (Plunkett et al., [@B65]), downregulated in inflamed tissue (Yang et al., [@B88]), and associated with migraine susceptibility (Jia et al., [@B30]). Parp10, a poly(ADP-ribose) polymerase upregulates pro-inflammatory pathways, and its inhibition attenuates neuropathy and neuroinflammation (Komirishetty et al., [@B37],[@B38]). Interferon regulatory factor Irf5 is increased in spinal microglia after peripheral nerve injury and drives P2X4R+ reactive microglia thereby gating neuropathic pain (Masuda et al., [@B50]). In Chronic atypical neutrophilic dermatosis with lipodystrophy and elevated temperature (CANDLE), a disease exhibiting joint pain symptoms, mutations have been found in proteasome subunit genes Psmb8 and Psmb9 (Arimochi et al., [@B3]). Genes from the Oas dsRNA sensor family, in particular Oas1a and Oasl2, are induced by lipopolysaccharides, which induce inflammatory pain (Lee et al., [@B45]). The E3 ubiquitin ligase Nedd4 is decreased in DRGs of SNI mice (Laedermann et al., [@B40]), and ribosomal protein Rps25, as well as other ribosomal proteins are downregulated in a model for HIV-associated neuropathic pain (Maratou et al., [@B49]). In line with the downregulation of Hdac1 in the blue cluster, HDAC inhibitors attenuate the development of hypersensitivity (Denk et al., [@B14]), restore C-fiber sensitivity (Matsushita et al., [@B51]), and induce behavioral anti-nociception (Tao et al., [@B79]). In addition, nerve injury increases the activity of Hdac1 and Ezh2 (Laumet et al., [@B44]). Pain responses depend on genes from the major histocompatibility complex (MHC; Guo et al., [@B26]), and the MHC-2 haplotype is involved in the incidence of postherpetic pain (Sato-Takeda et al., [@B69]). Further, MHC-2 molecules synergize with Toll-like receptor Tlr4 in inducing an innate immune response (Frei et al., [@B19]), and the lymphocyte antigen Ly86 is required in DRG neurons for functional Toll-like receptor Tlr4 signaling (Grace et al., [@B25]). Serpina3n is upregulated in mouse DRGs following nerve injury and attenuates neuropathic pain. Mice lacking Serpina3n develop more severe neuropathic pain symptoms than wildtypes (Vicuna et al., [@B85]). Another member of the Serpin family---Serping---has been implicated in hereditary angioedema, as mutations in this gene are associated with abdominal pain symptoms (Andrejevic et al., [@B2]). Finally, the Complement component genes C1r, C1s and C3 are upregulated after spinal nerve ligation (Levin et al., [@B46]). When comparing the emerging FD pain related genes with the global pain systems network for heat nociception (Neely et al., [@B55]) only epidermal growth factor receptor pathway substrate 8 (Eps8), alpha-N-acetylgalactosaminidase (Naga) and the proteasome subunit gene Psmb8 were contained. Together, this comprehensive literature search demonstrates considerable overlap of the current FD expression profile with genes implicated in nociception and pain disorders, suggesting relevant common pathogenesis components of FD pain and other pain disorders.

Despite constituting the first presentation of differentially expressed genes in DRG explants of α-Gal A^(−/0)^ mice, some limitations of the current analysis need to be considered. For instance, concerns have been raised that the α-Gal A^(−/0)^ mouse model might only resemble the later-onset phenotype of FD (Bangari et al., [@B4]). In kidney, Gb3 concentrations only reach 25% of that found in patients, and FD mouse life expectancy is normal (Taguchi et al., [@B78]). Therefore, the G3Stg/GLA knockout mouse has been generated and evaluated as a new FD mouse model, in which α-Gal A^(−/0)^ mice were crossbred with transgenic mice expressing the human Gb3 synthase. This resulted in symptomatic animals with increased Gb3 accumulation and progressive renal impairment (Taguchi et al., [@B78]). Another FD mouse model is the NOD/SCID immune deficiency mouse model with tissue specific Gb3 accumulation, but without clinical manifestation (Pacienza et al., [@B61]). Few data are available for these genetic models yet, but it would be important to know to what extent the three FD mouse models share the same differential gene expression. In addition, it would be of interest to explore the deregulation of gene expression in heterozygote females, which in humans and mice exhibit a considerably weaker phenotype than males (Uceyler et al., [@B83], [@B81]). Screening of homozygote females could be helpful to better understand the mechanisms and degree of X-chromosomal inactivation in female Fabry patients (Wilcox et al., [@B87]). Finally, it should be noted that gene targeting experiments are prone to a general phenomenon of background dependence that might confound the interpretation of results (Schalkwyk et al., [@B70]). In this study we controlled for this effect by using α-Gal A^(−/0)^ mice that had been backcrossed to an inbred C57BL/6J colony for the RT-qPCR validation of regulated genes.

Our in-depth bioinformatics analysis revealed a new set of genes and pathways that might be involved in the FD-associated small-nerve fiber neuropathy. These data give rise to subsequent functional studies on the importance of these deregulated genes for the pathogenesis of FD small fiber disease and neuropathic pain, and are expected to lead to the identification of novel treatment strategies, especially for neuropathic pain related symptoms in Fabry patients.
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